Korean J Pain.  2013 Apr;26(2):135-141. 10.3344/kjp.2013.26.2.135.

Effect of Ethyl Pyruvate on Paclitaxel-Induced Neuropathic Pain in Rats

• Choi SS
• Koh WU
• Nam JS
• Shin JW
• Leem JG
• Suh JH

• KMID: 1978657
• DOI: http://doi.org/10.3344/kjp.2013.26.2.135

Abstract

BACKGROUND
Although paclitaxel is a widely used chemotherapeutic agent for the treatment of solid cancers, side effects such as neuropathic pain lead to poor compliance and discontinuation of the therapy. Ethyl pyruvate (EP) is known to have analgesic effects in several pain models and may inhibit apoptosis. The present study was designed to investigate the analgesic effects of EP on mechanical allodynia and apoptosis in dorsal root ganglion (DRG) cells after paclitaxel administration.
METHODS
Rats were randomly divided into 3 groups: 1) a control group, which received only vehicle; 2) a paclitaxel group, which received paclitaxel; and 3) an EP group, which received EP after paclitaxel administration. Mechanical allodynia was tested before and at 7 and 14 days after final paclitaxel administration. Fourteen days after paclitaxel treatment, DRG apoptosis was determined by activated caspase-3 immunoreactivity (IR).
RESULTS
Post-treatment with EP did not significantly affect paclitaxel-induced allodynia, although it tended to slightly reduce sensitivities to mechanical stimuli after paclitaxel administration. After paclitaxel administration, an increase in caspase-3 IR in DRG cells was observed, which was co-localized with NF200-positive myelinated neurons. Post-treatment with EP decreased the paclitaxel-induced caspase-3 IR. Paclitaxel administration or post-treatment with EP did not alter the glial fibrillary acidic protein IRs in DRG cells.
CONCLUSIONS
Inhibition of apoptosis in DRG neurons by EP may not be critical in paclitaxel-induced mechanical allodynia.

Keyword

allodynia; apoptosis; dorsal root ganglion; ethyl pyruvate; paclitaxel

MeSH Terms

Animals
Apoptosis
Caspase 3
Compliance
Diagnosis-Related Groups
Ganglia, Spinal
Glial Fibrillary Acidic Protein
Hyperalgesia
Myelin Sheath
Neuralgia
Neurons
Paclitaxel
Pyruvates
Pyruvic Acid
Rats
Caspase 3
Glial Fibrillary Acidic Protein
Paclitaxel
Pyruvates
Pyruvic Acid

Figure

• 

  Fig. 1 The effect of ethyl pyruvate (EP) on paclitaxel-induced mechanical allodynia in rats. Groups of rats were injected i.p. with either vehicle (control) or paclitaxel (2 mg/kg on 4 alternate days). Another group of rats was treated i.p. with EP (50 mg/kg on 6 consecutive days) after final paclitaxel administration. Mechanical allodynia was tested before and at 7 and 14 days after final paclitaxel administration by application of von Frey filaments to the surface of the hind paw. The vertical bars indicate the standard error of the mean. The number of animals used for each group was 7 (*P < 0.05 and **P < 0.01 compared with the control group).

• 

  Fig. 2 The representative double immunofluorescence staining and quantitative analysis of activated caspase-3 and neurofilament 200 (NF200) in the rat dorsal root ganglion (DRG). Groups of rats were injected i.p. with either vehicle (control) or paclitaxel (2 mg/kg on 4 alternate days). Another group of rats was treated i.p. with either vehicle or ethyl pyruvate (EP, 50 mg/kg on 6 consecutive days) after final paclitaxel administration. Fourteen days after paclitaxel treatment, L5 DRG samples were immunostained with caspase-3, an indicator of apoptosis, and NF200, a marker of myelinated neurons. The co-localization of caspase-3 was visualized in a merged image. The arrow heads indicate where activated caspase-3 is co-localized with NF200. The scale bar represents 50 µm (A). The NF200 positive neurons that co-localized with caspase-3 were counted and are expressed as a percentage of the total neurons per section (***P < 0.001 compared with the control group, and †††P < 0.001 compared with paclitaxel group). Error bars represent SEM (B).

• 

  Fig. 3 The representative double immunofluorescence staining of activated caspase-3 and glial fibrillary acidic protein (GFAP) in the rat dorsal root ganglion (DRG). Groups of rats were injected i.p. with either vehicle (control) or paclitaxel (2 mg/kg on 4 alternate days). Another group of rats was treated i.p. with either vehicle or ethyl pyruvate (EP, 50 mg/kg on 6 consecutive days) after final paclitaxel administration. Fourteen days after paclitaxel treatment, L5 DRG samples were immunostained with caspase-3, an indicator of apoptosis, and GFAP, a marker of activated astrocytes. Neither paclitaxel nor post-treatment with EP affected GFAP- or caspase-3 IRs in DRG. The scale bar represents 50 µm.

Reference

1. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004; 4:253–265. PMID: 15057285.

2. Forsyth PA, Balmaceda C, Peterson K, Seidman AD, Brasher P, DeAngelis LM. Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing. J Neurooncol. 1997; 35:47–53. PMID: 9266440.

3. Postma TJ, Vermorken JB, Liefting AJ, Pinedo HM, Heimans JJ. Paclitaxel-induced neuropathy. Ann Oncol. 1995; 6:489–494. PMID: 7669713.

4. Cavaletti G, Bogliun G, Marzorati L, Zincone A, Marzola M, Colombo N, et al. Peripheral neurotoxicity of taxol in patients previously treated with cisplatin. Cancer. 1995; 75:1141–1150. PMID: 7850713.

5. Boyette-Davis J, Xin W, Zhang H, Dougherty PM. Intraepidermal nerve fiber loss corresponds to the development of taxol-induced hyperalgesia and can be prevented by treatment with minocycline. Pain. 2011; 152:308–313. PMID: 21145656.

6. Siau C, Xiao W, Bennett GJ. Paclitaxel- and vincristine-evoked painful peripheral neuropathies: loss of epidermal innervation and activation of Langerhans cells. Exp Neurol. 2006; 201:507–514. PMID: 16797537.

7. Melli G, Taiana M, Camozzi F, Triolo D, Podini P, Quattrini A, et al. Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy. Exp Neurol. 2008; 214:276–284. PMID: 18809400.

8. Scuteri A, Nicolini G, Miloso M, Bossi M, Cavaletti G, Windebank AJ, et al. Paclitaxel toxicity in post-mitotic dorsal root ganglion (DRG) cells. Anticancer Res. 2006; 26:1065–1070. PMID: 16619507.

9. Peters CM, Jimenez-Andrade JM, Kuskowski MA, Ghilardi JR, Mantyh PW. An evolving cellular pathology occurs in dorsal root ganglia, peripheral nerve and spinal cord following intravenous administration of paclitaxel in the rat. Brain Res. 2007; 1168:46–59. PMID: 17698044.

10. Zimmermann M. Pathobiology of neuropathic pain. Eur J Pharmacol. 2001; 429:23–37. PMID: 11698024.

11. Sekiguchi M, Sekiguchi Y, Konno S, Kobayashi H, Homma Y, Kikuchi S. Comparison of neuropathic pain and neuronal apoptosis following nerve root or spinal nerve compression. Eur Spine J. 2009; 18:1978–1985. PMID: 19543754.

12. Kim SH, Nam JS, Choi DK, Koh WW, Suh JH, Song JG, et al. Tumor necrosis factor-alpha and apoptosis following spinal nerve ligation injury in rats. Korean J Pain. 2011; 24:185–190. PMID: 22220239.

13. Yu YM, Kim JB, Lee KW, Kim SY, Han PL, Lee JK. Inhibition of the cerebral ischemic injury by ethyl pyruvate with a wide therapeutic window. Stroke. 2005; 36:2238–2243. PMID: 16141417.

14. Wang Q, Ding Q, Zhou Y, Gou X, Hou L, Chen S, et al. Ethyl pyruvate attenuates spinal cord ischemic injury with a wide therapeutic window through inhibiting high-mobility group box 1 release in rabbits. Anesthesiology. 2009; 110:1279–1286. PMID: 19417608.

15. Genovese T, Esposito E, Mazzon E, Di Paola R, Meli R, Caminiti R, et al. Beneficial effects of ethyl pyruvate in a mouse model of spinal cord injury. Shock. 2009; 32:217–227. PMID: 18948848.

16. Guo J, Zhang K, Ji Y, Jiang X, Zuo S. Effects of ethyl pyruvate on myocardial apoptosis and expression of Bcl-2 and Bax proteins after ischemia-reperfusion in rats. J Huazhong Univ Sci Technolog Med Sci. 2008; 28:281–283. PMID: 18563323.

17. Tsung A, Kaizu T, Nakao A, Shao L, Bucher B, Fink MP, et al. Ethyl pyruvate ameliorates liver ischemia-reperfusion injury by decreasing hepatic necrosis and apoptosis. Transplantation. 2005; 79:196–204. PMID: 15665768.

18. Choi DK, Leem JG, Shin JW, Suh JH. Effects of ethyl pyruvate on allodynia, TNF-α expression, and apoptosis in the dorsal root ganglion after spinal nerve ligation injury. Korean J Pain. 2012; 25:213–220. PMID: 23091681.

19. Lee MJ, Jang M, Jung HS, Kim SH, Cho IH. Ethyl pyruvate attenuates formalin-induced inflammatory nociception by inhibiting neuronal ERK phosphorylation. Mol Pain. 2012; 8:40. PMID: 22640699.

20. Jacobs CC, Holcombe SJ, Cook VL, Gandy JC, Hauptman JG, Sordillo LM. Ethyl pyruvate diminishes the inflammatory response to lipopolysaccharide infusion in horses. Equine Vet J. 2012; [in press].

21. Matsumoto M, Inoue M, Hald A, Xie W, Ueda H. Inhibition of paclitaxel-induced A-fiber hypersensitization by gabapentin. J Pharmacol Exp Ther. 2006; 318:735–740. PMID: 16687474.

22. Polomano RC, Mannes AJ, Clark US, Bennett GJ. A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel. Pain. 2001; 94:293–304. PMID: 11731066.

23. Choi JS, Lee MS, Jeong JW. Ethyl pyruvate has a neuroprotective effect through activation of extracellular signal-regulated kinase in Parkinson's disease model. Biochem Biophys Res Commun. 2010; 394:854–858. PMID: 20307492.

24. Yang R, Shaufl AL, Killeen ME, Fink MP. Ethyl pyruvate ameliorates liver injury secondary to severe acute pancreatitis. J Surg Res. 2009; 153:302–309. PMID: 19027919.

25. Li Y, Dorsi MJ, Meyer RA, Belzberg AJ. Mechanical hyperalgesia after an L5 spinal nerve lesion in the rat is not dependent on input from injured nerve fibers. Pain. 2000; 85:493–502. PMID: 10781924.

26. Choi JI, Kim WM, Yoon MH, Lee HG. Antiallodynic effect of thalidomide and morphine on rat spinal nerve ligation-induced neuropathic pain. Korean J Pain. 2010; 23:172–178. PMID: 20830262.

27. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods. 1994; 53:55–63. PMID: 7990513.

28. Flatters SJ, Bennett GJ. Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: evidence for mitochondrial dysfunction. Pain. 2006; 122:245–257. PMID: 16530964.

29. Pascual D, Goicoechea C, Suardíaz M, Martín MI. A cannabinoid agonist, WIN 55,212-2, reduces neuropathic nociception induced by paclitaxel in rats. Pain. 2005; 118:23–34. PMID: 16213089.

30. Xiao WH, Bennett GJ. Chemotherapy-evoked neuropathic pain: abnormal spontaneous discharge in A-fiber and C-fiber primary afferent neurons and its suppression by acetyl-L-carnitine. Pain. 2008; 135:262–270. PMID: 17659836.

31. Zhang J, Tuckett RP. Comparison of paclitaxel and cisplatin effects on the slowly adapting type I mechanoreceptor. Brain Res. 2008; 1214:50–57. PMID: 18466884.

32. Figueroa-Masot XA, Hetman M, Higgins MJ, Kokot N, Xia Z. Taxol induces apoptosis in cortical neurons by a mechanism independent of Bcl-2 phosphorylation. J Neurosci. 2001; 21:4657–4667. PMID: 11425893.

33. Jang HJ, Hwang S, Cho KY, Kim do K, Chay KO, Kim JK. Taxol induces oxidative neuronal cell death by enhancing the activity of NADPH oxidase in mouse cortical cultures. Neurosci Lett. 2008; 443:17–22. PMID: 18672029.

34. Chen M, Wang J. Initiator caspases in apoptosis signaling pathways. Apoptosis. 2002; 7:313–319. PMID: 12101390.

35. Joseph EK, Levine JD. Caspase signalling in neuropathic and inflammatory pain in the rat. Eur J Neurosci. 2004; 20:2896–2902. PMID: 15579143.

36. Burkhart CA, Berman JW, Swindell CS, Horwitz SB. Relationship between the structure of taxol and other taxanes on induction of tumor necrosis factor-alpha gene expression and cytotoxicity. Cancer Res. 1994; 54:5779–5782. PMID: 7954398.

37. Manthey CL, Brandes ME, Perera PY, Vogel SN. Taxol increases steady-state levels of lipopolysaccharide-inducible genes and protein-tyrosine phosphorylation in murine macrophages. J Immunol. 1992; 149:2459–2465. PMID: 1356126.

38. Kiguchi N, Kobayashi Y, Kishioka S. Chemokines and cytokines in neuroinflammation leading to neuropathic pain. Curr Opin Pharmacol. 2012; 12:55–61. PMID: 22019566.

39. Wang XM, Lehky TJ, Brell JM, Dorsey SG. Discovering cytokines as targets for chemotherapy-induced painful peripheral neuropathy. Cytokine. 2012; 59:3–9. PMID: 22537849.

40. Zhang H, Yoon SY, Zhang H, Dougherty PM. Evidence that spinal astrocytes but not microglia contribute to the pathogenesis of Paclitaxel-induced painful neuropathy. J Pain. 2012; 13:293–303. PMID: 22285612.

41. Burgos E, Gómez-Nicola D, Pascual D, Martín MI, Nieto-Sampedro M, Goicoechea C. Cannabinoid agonist WIN 55,212-2 prevents the development of paclitaxel-induced peripheral neuropathy in rats. Possible involvement of spinal glial cells. Eur J Pharmacol. 2012; 682:62–72. PMID: 22374260.